A randomized phase II clinical trial of personalized peptide vaccination with metronomic low-dose cyclophosphamide in patients with metastatic castration-resistant prostate cancer

Cancer Immunology, Immunotherapy

Volumn 65, Issue 2, 2016, Pages 151-160

  Noguchi, Masanori ^a   Moriya, Fukuko ^a   Koga, Noriko ^a   Matsueda, Satoko ^a   Sasada, Tetsuro ^b   Yamada, Akira ^a   Kakuma, Tatsuyuki ^a   Itoh, Kyogo ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KANAGAWA CANCER CENTER   (Japan)

Author keywords

Cyclophosphamide; Immunotherapy; Myeloid derived suppressor cell; Peptide vaccination; Phase II trial; Regulatory T cell

Indexed keywords

ALKALINE PHOSPHATASE; CANCER VACCINE; CYCLOPHOSPHAMIDE; IMMUNOGLOBULIN G; PEPTIDE VACCINE; PERSONALIZED PEPTIDE VACCINE; UNCLASSIFIED DRUG; PEPTIDE; SUBUNIT VACCINE;

ADULT; AGED; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CASTRATION RESISTANT PROSTATE CANCER; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DRUG EFFICACY; DRUG SAFETY; HUMAN; HUMORAL IMMUNITY; HYPONATREMIA; IMMUNE RESPONSE; INJECTION SITE REACTION; LOSS OF APPETITE; LOW DRUG DOSE; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; METRONOMIC DRUG ADMINISTRATION; MONOTHERAPY; MYELOID DERIVED SUPPRESSOR CELL; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL EDEMA; PERSONALIZED MEDICINE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; REGULATORY T LYMPHOCYTE; SIDE EFFECT; SUPPRESSOR CELL; THROMBOCYTOPENIA; CANCER GRADING; CHEMISTRY; CLINICAL TRIAL; IMMUNOLOGY; METABOLISM; METASTASIS; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PROCEDURES; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VERY ELDERLY;

ADMINISTRATION, METRONOMIC; AGED; AGED, 80 AND OVER; CANCER VACCINES; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; HUMANS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM METASTASIS; PEPTIDES; PRECISION MEDICINE; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; SURVIVAL ANALYSIS; T-LYMPHOCYTES, CYTOTOXIC; T-LYMPHOCYTES, REGULATORY; TREATMENT OUTCOME; VACCINES, SUBUNIT;

EID: 84955701712     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-015-1781-6     Document Type: Article

References (38)

1. Quatromoni JG, Eruslanov E (2012) Tumor-associated macrophages: function, phenotype, and link to prognosis in human lung cancer. Am J Transl Res 4:376–389
2. +CD25high T cells are enriched in the tumor and peripheral blood of prostate cancer patients. J Immunol 177:7398–7405
3. Sfanos KS, Bruno TC, Maris CH, Xu L, Thoburn CJ, DeMarzo AM et al (2008) Phenotypic analysis of prostate-infiltrating lymphocytes reveals TH17 and Treg skewing. Clin Cancer Res 14:3254–3261
4. Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P et al (2004) Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 10:942–949
5. + regulatory T cells in the peripheral blood of advanced stage lung cancer patients. Med Oncol 27:29–33
6. + regulatory T cells in patients with gastro-intestinal malignancies: possible involvement of regulatory T cells in disease progression. Cancer 98:1089–1099
7. + T cells in B-cell non-Hodgkin lymphoma. Blood 107:3639–3646
8. Serafini P, Mgebroff S, Noonan K, Borrello I (2008) Myeloid-derived suppressor cells promote cross-tolerance in B-cell lymphoma by expanding regulatory T cells. Cancer Res 68:5439–5449
9. Diaz-Montero CM, Salem ML, Nishimura MI, Garrett-Mayer E, Cole DJ, Montero AJ (2009) Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunol Immunother 58:49–59
10. Sasada T, Komatsu N, Suekane S, Yamada A, Noguchi M, Itoh K (2010) Overcoming the hurdles of randomized clinical trials of therapeutic cancer vaccine. Eur J Cancer 46:1514–1519
11. Noguchi M, Sasada T, Itoh K (2013) Personalized peptide vaccination: a new approach for advanced cancer as therapeutic cancer vaccine. Cancer Immunol Immunother 62:919–929
12. Noguchi M, Kobayashi K, Suetsugu N, Tomiyasu K, Suekane S, Yamada A et al (2003) Induction of cellular and humoral immune responses to tumor cells and peptides in HLA-A24 positive hormone-refractory prostate cancer patients by peptide vaccination. Prostate 57:80–92
13. Noguchi M, Itoh K, Suekane S, Yao A, Suetsugu N, Katagiri K et al (2004) Phase I trial of patient-oriented vaccination in HLA-A2 positive patients with metastatic hormone refractory prostate cancer. Cancer Sci 95:77–84
14. Noguchi M, Uemura H, Naito S, Akaza H, Yamada A, Itoh K (2011) A phase I study of personalized peptide vaccination using 14 kinds of vaccine in combination with low-dose estramustine in HLA-A24-positive patients with castration-resistant prostate cancer. Prostate 71:470–479
15. Noguchi M, Kakuma T, Uemura H, Nasu Y, Kumon H, Hirao Y et al (2010) A randomized phase II trial of personalized peptide vaccine plus low dose estramustine phosphate (EMP) versus standard dose EMP in patients with castration resistant prostate cancer. Cancer Immunol Immunother 59:1001–1009
16. + T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood 105:2862–2868
17. Hamano Y, Sugimoto H, Soubasakos MA, Kieran M, Olsen BR, Lawler J et al (2004) Thrombospondin-1 associated with tumor microenvironment contributed to low-dose cyclophosphamide-mediated endothelial cell apoptosis and tumor growth suppression. Cancer Res 64:1570–1574
18. Komatsu N, Shichijo S, Nakagawa M, Itoh K (2004) New multiplexed flow cytometric assay to measure anti-peptide antibody: a novel tool for monitoring immune responses to peptides used for immunization. Scand J Clin Lab Invest 64:535–545
19. Yoshiyama K, Terazaki Y, Matsueda S, Shichijo S, Noguchi M, Yamada A et al (2012) Personalized peptide vaccination in patients with refractory non-small cell lung cancer. Int J Oncol 40:1492–1500
20. Colleoni M, Rocca A, Sandri MT, Zorzino L, Masci G, Nolè F et al (2002) Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels. Ann Oncol 13:73–80
21. Scharovsky OG, Mainetti LE, Rozados VR (2009) Metronomic chemotherapy: changing the paradigm that more is better. Curr Oncol 16:7–15
22. Nelius T, Rinard K, Filleur S (2011) Oral/metronomic cyclophosphamide-based chemotherapy as option for patients with castration-refractory prostate cancer—review of the literature. Cancer Treat Rev 37:444–455
23. + regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. Eur J Immunol 34:336–344
24. + regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother 56:641–648
25. Gabrilovich DI, Bronte V, Chen SH, Colombo MP, Ochoa A, Ostrand-Rosenberg S et al (2007) The terminology issue for myeloid-derived suppressor cells. Cancer Res 67:425
26. Angulo I, de las Heras FG, Garcia-Bustos JF, Gargallo D, Muñoz-Fernández MA, Fresno M (2000) Nitric oxide-producing CD11b(+)Ly-6G(Gr-1)(+)CD31(ER-MP12)(+) cells in the spleen of cyclophosphamide-treated mice: implications for T-cell responses in immunosuppressed mice. Blood 95:212–220
27. Peláez B, Campillo JA, López-Asenjo JA, Subiza JL (2001) Cyclophosphamide induces the development of early myeloid cells suppressing tumor cell growth by a nitric oxide-dependent mechanism. J Immunol 166:6608–6615
28. + T cells: a common basis between tumor immunity and auto immunity. J Immunol 163:5211–5218
29. + regulatory T cells through GITR breaks immunological self-tolerance. Nat Immunol 3:135–142
30. Yang R, Cai Z, Zhng Yutzy WH 4th, Roby KF, Roden RB (2006) CD80 in immune suppression by mouse ovarian carcinoma-associated Gr-1+ CD11b+ myeloid cells. Cancer Res 66:6807–6815
31. Huang B, Pan PY, Li Q, Sato AI, Levy DE, Bromberg J et al (2006) Gr-1+ CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res 66:1123–1131
32. + T-cell response to peptide vaccination: creation of a beneficial host microenvironment involving type I IFNs and myeloid cells. J Immunother 30:40–53
33. + T cells to the antitumor immune response. J Exp Med 201:1591–1602
34. Berd D, Maguire HC Jr, Mastrangelo MJ (1986) Induction of cell-mediated immunity to autologous melanoma cells and regression of metastasis after treatment with a melanoma cell vaccine preceded by cyclophosphamide. Cancer Res 46:2572–2577
35. Sahasrabudhe DM, deKernion JB, Pontes JE, Ryan DM, O’Donnell RW, Marquis DM et al (1986) Specific immunotherapy with suppressor function inhibition for metastatic renal carcinoma. J Biol Response Mod 5:581–594
36. + T lymphocytes. Clin Exp Immunol 150:523–530
37. Emens LA, Asquith JM, Leatherman JM, Kobrin BJ, Petrik S, Laiko M et al (2009) Timed sequential treatment with cyclophosphamide, doxorubicin, and an allogeneic granulocyte-macrophage colony-stimulating factor-secreting breast tumor vaccine: a chemotherapy dose-ranging factorial study of safety and immune activation. J Clin Oncol 27:5911–5918
38. Ge Y, Domschke C, Stoiber N, Schott S, Heil J, Rom J et al (2012) Metronomic cyclophosphamide treatment in metastasized breast cancer patients: immunological effects and clinical outcome. Cancer Immunol Immunother 61:353–362